Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.94% | 88.65 | 1.3% | $803.98m | |
| AMGN | Amgen Inc. | -0.76% | 185.50 | 1.2% | $628.99m | |
| GILD | Gilead Sciences, Inc. | -2.14% | 65.55 | 0.9% | $482.29m | |
| BIIB | Biogen Inc. | -4.17% | 321.17 | 1.3% | $427.44m | |
| ILMN | Illumina, Inc. | -1.77% | 296.88 | 3.5% | $311.35m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.92% | 418.62 | 2.6% | $290.18m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.55% | 183.06 | 1.9% | $253.58m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.76% | 127.55 | 2.0% | $219.68m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.87% | 136.54 | 15.4% | $152.33m | |
| A | Agilent Technologies, Inc. | -0.83% | 77.91 | 1.6% | $150.84m | |
| EXAS | Exact Sciences Corporation | -0.42% | 83.28 | 25.3% | $132.28m | |
| INCY | Incyte Corporation | -0.49% | 83.33 | 2.5% | $111.93m | |
| ARRY | Array BioPharma Inc. | -1.99% | 22.71 | 8.2% | $108.01m | |
| EXEL | Exelixis, Inc. | -0.09% | 21.22 | 6.4% | $82.07m | |
| NBIX | Neurocrine Biosciences, Inc. | -2.58% | 77.31 | 5.1% | $77.22m |
Company Profile
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.